CBD & Hemp
Latest French CBD Crackdown To Be Challenged In Court
French trade groups are seeking to overturn the ban on the sale of CBD food supplements in an attempted re-run
Peter
June 3, 2026
French trade groups are seeking to overturn the ban on the sale of CBD food supplements in an attempted re-run
Last week (April 27), the deadline for Greek industry stakeholders to have their say on a controversial new hemp ban
The long and arduous journey to regulate cannabidiol (CBD) in Europe, which began in 2018 with the European Union’s classification
As the federal campaign to clamp down on intoxicating hemp in the US rolls on, the Drug Enforcement Administration (DEA)
In April 2025, the Italian government used emergency constitutional powers to bypass parliament and reclassify non-intoxicating hemp as a narcotic,
US Medicare patients have now been given access to cannabidiol (CBD) products through a landmark federal pilot scheme, helping boost
New Zealand’s medical cannabis market grew a further 25% in 2025, according to the latest official figures, seeing the country
The CBD sector has had a turbulent few weeks on both sides of the Channel, with the European Food Safety
Sorting Evidence from Anecdote As global cannabis research accelerates, the number of published studies has never been higher, but not
Cannabis is now one of the most frequently discussed therapeutic agents in modern medicine, driven by expanding access programmes and
Cannabis Stocks Surge on Trump Video Global cannabis stocks have enjoyed a considerable, but likely temporary, run this week, after
This opinion piece was written by Calvin Rasode, Vice President, Marketing, Brains Bioceutical When Donald Trump tweets, the world pays
The European Commission (EC) is considering a major overhaul of regulations surrounding hemp across the Union, potentially marking a step
As part of the FSA’s re-energised efforts to push forward with the long-running CBD novel foods approvals process, the agency
This morning, the UK’s Food Standards Agency (FSA) announced some significant updates to its multi-year CBD Novel Foods approvals process,
Welcome to Business of Cannabis’ new weekly strategic digest tracking the financial health, market moves, and corporate developments shaping the
One of the key differences between medical cannabis and other more traditional treatments is the highly personalised nature of how each patient is affected.
DeFloria, a joint venture between Charlotte’s Web Holdings and Ajna BioSciences, is advancing toward the start of its Phase 2 clinical trial for AJA001, a cannabinoid-based (FDA) botanical drug developed to treat behavioral symptoms associated with autism spectrum disorder (ASD).
We won’t spam you